FDA OKs Reintroduction of Tegaserod for IBS-C in Women Under 65
The FDA will allow tegaserod back on the market after an advisory committee recommended its use in women without a history of CV ischemic disease. FDA Approvals …read more
The FDA will allow tegaserod back on the market after an advisory committee recommended its use in women without a history of CV ischemic disease. FDA Approvals …read more
In long-term follow-up, Diabetes Prevention Program participants randomized to metformin during the trial continue to have lower rates of developing type 2 diabetes. Medscape Medical News …read more
The impact of HPV type 16/18 vaccination: Dr Maurie Markman discusses recent results from a study of cervical precancers from 2008 to 2014. Medscape Oncology …read more
New research finds an association between the ratio of two estrogen metabolites and the risk of all-cause mortality among women with breast cancer. …read more